Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 12/20 | 0.65 |
| ▸ | MMP9 | P14780 | 6/20 | 0.62 |
| ▸ | MMP2 | P08253 | 5/20 | 0.62 |
| ▸ | MMP13 | P45452 | 5/20 | 0.61 |
| ▸ | MMP1 | P03956 | 3/20 | 0.61 |
| ▸ | MMP8 | P22894 | 3/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346333 | 1.00 | BMP1 (0.65) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL26770039 | 0.91 | MMP9 (0.77) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL2858317 | 0.91 | BMP1 (0.58) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL2858314 | 0.91 | BMP1 (0.58) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL2873393 | 0.90 | MMP2 (0.64) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2873395 | 0.90 | MMP2 (0.64) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL6414515 | 0.89 | BMP1 (0.61) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL2680842 | 0.89 | BMP1 (0.61) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL2881007 | 0.89 | MMP2 (0.63) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2881004 | 0.89 | MMP2 (0.63) | BMP1MMP9MMP2MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |